Biosimilar trastuzumab similar to Herceptin in non-clinical study

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Biosimilar trastuzumab similar to Herceptin in non-clinical study

Biosimilars/Research | Posted 08/08/2014 0 Post your comment

Comparative non-clinical assessments of the proposed trastuzumab biosimilar PF-05280014 and the originator product (Herceptin) sourced in the US and in Europe showed similar structural properties, tumour cell growth inhibition properties and pharmacokinetic profiles, as well as safety profiles [1].

In this study, physicochemical and functional similarity were assessed between PF-05280014, trastuzumab-US and trastuzumab-EU using peptide mapping. In vitro functional similarity was assessed using a tumour cell proliferation inhibition assay using the HER2-overexpression metastatic breast carcinoma cell line, SKBR-3. To determine the in vivo pharmacokinetics/tolerability male CD-1 mice were administered a single-dose (0, 1, 10, or 100 mg/kg) of PF-05280014, trastuzumab-US or trastuzumab-EU.

The results of peptide mapping of PF-05280014, trastuzumab-US, and trastuzumab-EU showed similar chromatographic profiles between the three drugs. The tumour cell growth inhibition of PF-05280014 was similar to trastuzumab-US and trastuzumab-EU. C_max and area under the concentration time curve (AUC) values in mice were similar and dose-dependent across the three monoclonal antibodies at all doses. Clearance (CL) and volume of distribution (V_ss) values were also similar and dose-independent. The incidence of anti-drug antibodies was low (~10%) and also similar across all dose levels and the three monoclonal antibodies.

PF-05280014, trastuzumab-US, and trastuzumab-EU were well tolerated during the 4-month observation period following a single dose of up to 100 mg/kg.

The authors therefore concluded that the results of these studies support the development of PF-05280014 as a proposed biosimilar to Herceptin (trastuzumab).

Conflict of interest
This study was funded by Pfizer. All authors of the of the research paper [1] are employees of either Pfizer or Covance, contracted by Pfizer for this study.

Biocon and Mylan challenge Indian ban on trastuzumab ‘similar biologics’

Reference
1. Hurst S, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and Trastuzumab (Herceptin®). BioDrugs. 2014. [Epub ahead of print]

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.